APP and Alzheimer disease: In 2015, Prof. Kapurniotu of the Technical University of Munich, Germany506 designed a series of peptide-based small molecule inhibitors based on the protein sequences of islet amyloid polypeptide (IAPP), a type of small molecule inhibitor that can inhibit the root causes of amyloid proteins (amyloid- beta peptide and IAPP) aggregation, thus reducing the cytotoxicity of amyloid fibrils, and providing a new idea for the treatment of Alzheimer’s disease in the clinic.